Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats

JACC Basic Transl Sci. 2023 May 31;8(9):1160-1176. doi: 10.1016/j.jacbts.2023.03.003. eCollection 2023 Sep.

Abstract

Chronic kidney disease is a global health problem affecting 10% to 12% of the population. Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and diastolic dysfunction. Dysregulation of neuregulin-1β signaling in the heart is a known contributor to heart failure. The systemically administered recombinant human neuregulin-1β for 10 days in our 5/6 nephrectomy-induced model of chronic kidney disease alleviated the progression of uremic cardiomyopathy and kidney dysfunction in type 4 cardiorenal syndrome. The currently presented positive preclinical data warrant clinical studies to confirm the beneficial effects of recombinant human neuregulin-1β in patients with chronic kidney disease.

Keywords: cardiac fibrosis; chronic kidney disease; left ventricular hypertrophy; recombinant human neuregulin-1β; uremic cardiomyopathy.